Novan Inc

Novan — Corporate Update (September 2021)

35 slides from Novan's corporate update, Sep 9, 2021

  1. Slide 1: Nitric Oxide-Based Medicine Corporate Update

    Nitric Oxide-Based Medicine N A S D A Q : N O V N | n o v a n . c o m C O R P O R AT E U P D AT E / S E P T E M B E R 9 , 2 0 2 1 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    NOVAN.COM FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of the Company’s NITRICIL™ platform technology, the Company’s pharmaceutical development of nitric oxide-releasing product c

  3. Slide 3: A world leader in nitric oxide-based science, technology, and clinical translation

    A world leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies

  4. Slide 4: Agenda

    NOVAN.COM AGENDA 4 A Compelling Investment Opportunity Our History of R&D and Innovation Our Near-Term Strategy Our Commercialization Plan Our Full Opportunity Why Novan – Why Now

  5. Slide 5: A Compelling Investment Opportunity

    NOVAN.COM A COMPELLING INVESTMENT OPPORTUNITY Clinically proven platform technology, NITRICIL™ Robust body of data with nearly 4,000 treated subjects supporting anti-microbial and anti-inflammatory properties Positive topline results from pivotal Phase 3 study of SB206 in patients with molluscum con

  6. Slide 6: Three NDAs Planned Over Three Years

    NOVAN.COM THREE NDAs PLANNED OVER THREE YEARS 6 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval NDA Submission Targeted Novan Revenue Retention2 DERMATOLOGY SB206 Molluscum Q3 2022 ~85% N. America3 >95% ROW (ex. Japan4) SB204 Acne Vulgaris 20241 ~95% N. America >95% ROW (ex. Ja

  7. Slide 7: Potential Value Creation

    NOVAN.COM Potential Value Creation 7 Product Candidate SB206 SB204 SB019 Type Topical Gel Topical Gel Nasal Suspension Indication Molluscum Acne COVID-19 Potential Global Addressable Market ~12 Million1 ~733 Million2 ~134 Million3 Current Treatment Options In-office procedures; off label scripts Ant

  8. Slide 8: NITRICIL

    NOVAN.COM NITRICIL™ 8 Clinically proven proprietary nitric oxide (NO)-based technology platform Macromolecular New Chemical Entities (NCEs) Storage: ability to store therapeutic quantities of NO Tunability: pH-controlled NO release profiles Targeted: delivery of NO to site of infection or inflammati

  9. Slide 9: Value Drivers Beyond 2024

    NOVAN.COM VALUE DRIVERS BEYOND 2024 9 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 DERMATOLOGY SB414 Atopic Dermatitis Psoriasis SB208 Tinea Pedis MEN’S AND WOMEN’S HEALTH SB207 Genital Warts WH504 High-Risk HPV WH602 High-Risk HPV COMPANION ANIMAL NVN4100 Various Ongoing Ongoing

  10. Slide 10: Strategy Towards Driving Near-Term Stakeholder Value

    STRATEGY TOWARDS DRIVING NEAR-TERM STAKEHOLDER VALUE Leverage core synergies of science, capital, resources and patient needs to create value by bringing new nitric oxide-based medicines to market

  11. Slide 11: SB206 Molluscum Contagiosum

    NOVAN.COM SB206 Molluscum Contagiosum 11 Positive topline results from pivotal Phase 3 with NDA submission targeted Q3 2022

  12. Slide 12: Molluscum Market Potential for SB206

    NOVAN.COM MOLLUSCUM MARKET POTENTIAL FOR SB206 Contagious skin infection caused by the molluscipoxvirus, a double-stranded DNA virus 12 High unmet medical need for topical at-home solution Prevalence rate in children 0-16 years old is 5.1% - 11.5% in the U.S.1 U.S. addressable market of ~6 million2

  13. Slide 13: Pivotal Phase 3: Primary Efficacy Endpoint

    NOVAN.COM PIVOTAL PHASE 3: PRIMARY EFFICACY ENDPOINT 13 Complete Clearance of Lesions 0.9% 3.6% 11.6% 19.7% 1.4% 7.2% 19.6% 32.4% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% Week 2 Week 4 Week 8 Week 12 Vehicle SB206 p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001 * ** *** **** **** **

  14. Slide 14: Pivotal Phase 3: Secondary Endpoints

    NOVAN.COM PIVOTAL PHASE 3: SECONDARY ENDPOINTS 14 90% Clearance and 0 or 1 Remaining Lesions at Week 12 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00% 45.00% 50.00% 90% Clearance at Week 12 0 or 1 Lesions at Week 12 Vehicle SB206 ******** p-value <0.0001****

  15. Slide 15: Pivotal Phase 3: Secondary Endpoint - Change at Week 12

    NOVAN.COM PIVOTAL PHASE 3: SECONDARY ENDPOINT - CHANGE AT WEEK 4 15 -60% -50% -40% -30% -20% -10% 0% BL Week 2 Week 4 Week 8 Week 12 Vehicle SB206 p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001 * ** *** **** **** **** **** *** % Change From Baseline Lesion Count

  16. Slide 16: Path Towards Potential Approval

    NOVAN.COM PATH TOWARDS POTENTIAL APPROVAL 16 SB206 Targets to be the First FDA-Approved, In-Home Topical Treatment for Molluscum Finalize B-SIMPLE4 Week-24 Readout 3Q 2021 1H 2022 3Q 2022 Launch Pre-Commercial Activities NDA-Enabling Stability Testing Pre-NDA Meeting with FDA Submit New Drug Applica

  17. Slide 17: SB206 Commercialization Plan

    NOVAN.COMNOVAN.COM 17 SB206 COMMERCIALIZATION PLAN Commercialization of SB206 with Syneos Health’s Integrated Support Model, if Approved End-to-end commercial solution provider with proven track record of supporting successful commercial launches Provides immediate access to robust, existing commerc

  18. Slide 18: SB206 Commercial Approach

    NOVAN.COM SB206 COMMERCIAL APPROACH 18 • Communication • Education • Evidence Base • Early Engagement • Economic Burden • Commercial Formulary • Digital Health • Build the brand • Establish Differentiation • Efficiently Target Stakeholders • Amplify Reach Generate data and build the holistic evidenc

  19. Slide 19: Competitive Landscape

    NOVAN.COM COMPETITIVE LANDSCAPE 191. Syneos Health Consulting Primary (n=40 Pediatricians, n=39 Dermatologists, n=4 Pediatric Dermatologists) and Secondary Research (2019) Today, approximately 1.3 million new U.S. cases diagnosed annually1 Potential Therapy Characteristics Topical – SB206 In-home tr

  20. Slide 20: SB204 Acne Vulgaris

    NOVAN.COM SB204 Acne Vulgaris Late-stage asset with two completed Phase 3 studies Priority Pipeline Expansion 20

  21. Slide 21: SB204: Advance Development for Acne Vulgaris

    NOVAN.COM SB204: ADVANCE DEVELOPMENT FOR ACNE VULGARIS Potential advantages over other topical therapies for the most common form of acne 21 Multi-factorial mechanism of action, including anti-bacterial and anti-inflammatory Convenience of once daily application Excellent local tolerability and favo

  22. Slide 22: Data from Positive Phase 3 Study

    NOVAN.COM DATA FROM POSITIVE PHASE 3 STUDY 22*Analysis includes all patients who were randomized. Absolute changes in lesion count reduction are shown as LSMean NI-AC302 ITT* (n = 1327) Non-Inflammatory Lesion Reduction SB204 -14.8 Vehicle -12.1 p-value p=0.001 Inflammatory Lesion Reduction SB204 -1

  23. Slide 23: SB204 Acne Vulgaris: Why we are planning for success

    NOVAN.COM SB204 Acne Vulgaris: Why we are planning for success 23 FDA GUIDANCE: JUST ONE MORE PIVOTAL PHASE 3 TRIAL AC302 was a successful pivotal Phase 3 trial across all three co-primary endpoints Consistent results across AC301 and AC302 for two of three co-primary endpoints Positive B-SIMPLE4 re

  24. Slide 24: Regulatory Path for SB204 in Acne

    NOVAN.COM REGULATORY PATH FOR SB204 IN ACNE 24 Targeted Timeline: Two Phase 3 studies completed in 2017 One pivotal Phase 3 study to be conducted Size of trial estimated to include >1,000 patients 3 co-primary endpoints (non-inflammatory lesions, inflammatory lesions, IGA success) Prepare for Pivota

  25. Slide 25: Acne Vulgaris Market Potential

    NOVAN.COM ACNE VULGARIS MARKET POTENTIAL We believe among dermatology health-care providers there remains a significant unmet need for novel mechanisms of action with favorable tolerability profiles to improve patient outcomes in acne 25 ~50 million people with acne in the U.S.1 Topical U.S. acne ma

  26. Slide 26: SB019 COVID-19

    NOVAN.COM SB019 COVID-19 26 Phase 1 in healthy volunteers in 1H 2022

  27. Slide 27: SB019: Advance Development for COVID-19

    NOVAN.COM SB019: Advance Development for COVID-19 Intranasal administration may reduce viral burden in the nasal epithelium and lead to reduced transmission, disrupted disease progression, and alleviated symptoms 27 Nitric oxide known to have potent anti-viral properties Strong preclinical and clini

  28. Slide 28: Regulatory Path for SB019 in COVID-19

    NOVAN.COM REGULATORY PATH FOR SB019 IN COVID-19 28 Pre-clinical IND enabling studies completed1 Candidate formulation administered intranasally in animals Berdazimer sodium well-tolerated up to the maximum dose tested Drug-device combination in development for potential Phase 2/3 study(s) 1. Assumes

  29. Slide 29: The Full Opportunity

    NOVAN.COM The Full Opportunity Building a fully integrated dermatology and anti-infectives company 29

  30. Slide 30: Robust IP Protection

    NOVAN.COM ROBUST IP PROTECTION Over 35 issued US patents, over 125 issued non-US patents and over 85 pending applications throughout the world 30 NITRICIL™ Technology Patent Expiration1 Composition of Matter to 2026 Method of Manufacture to 2032 Formulation Science Formulation Composition and Manufa

  31. Slide 31: Milestones in Next Months

    NOVAN.COM MILESTONES IN NEXT 12 MONTHS 31 2H 2021 1H 2022 Final Safety Results B-SIMPLE4 for SB206 Launch Pre-Commercial Activities for SB206 Submit SB019 Pre-IND Initiate Phase 1 with SB019 SB206 Pre-NDA Meeting with FDA Submit SB206 NDA

  32. Slide 32: Fully Integrated Team Specifically Designed to Execute Strategy

    NOVAN.COM FULLY INTEGRATED TEAM SPECIFICALLY DESIGNED TO EXECUTE STRATEGY 32 Tomoko Maeda-Chubachi, MD, Ph.D., MBA Chief Medical Officer John M. Gay, CPA Chief Financial Officer Carri Geer, Ph.D. Chief Technology Officer Paula Brown Stafford, MPH Chairman and Chief Executive Officer Leveraging Exten

  33. Slide 33: Novan PRIDE Underpins Our Efforts

    NOVAN.COM NOVAN PRIDE UNDERPINS OUR EFFORTS 33

  34. Slide 34: Why Novan, Why Now

    NOVAN.COM Why Novan, Why Now A world leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies 34 NITRICIL™ technology platform allows stable, tunable, and targeted delivery of therapeutic quantities of NO Robust body of data w

  35. Slide 35: Thank You

    Nitric Oxide-Based Medicine N A S D A Q : N O V N | n o v a n . c o m INVESTOR RELATIONS JTC Team 833.475.8247 [email protected] Thank You!

Novan — Corporate Update (September 2021) on 6ix